9/11/2013 6:38:02 AM
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Roger S. Newton, Ph.D., Esperion’s executive chairman, chief scientific officer and company founder, will present at the Stifel Nicolaus 2013 Healthcare Conference in Boston.
Help employers find you! Check out all the jobs and post your resume.
comments powered by